SIRA Opioid Management Changes: What Claims Managers Need to Know

Navigate the 2020 and 2025 SIRA opioid reforms to deliver safer, person-centred medication management in workers compensation claims

Published 4 April 2026

The Gap Between Policy and Practice

Your role as a claims manager is under pressure. Workers are in pain, doctors are prescribing opioids, and SIRA has set new expectations. But the gap between what SIRA recommends and what actually happens on the ground remains substantial. Many claims managers still treat opioid oversight as an administrative checkbox: reviewing prescription requests, approving dose increases, documenting discussions. Meanwhile, workers languish on chronic opioids without clear functional improvement, while prescribers and you operate in silos.

The Workers Compensation Act 1987 (NSW) places a duty of care on insurers to manage injured workers' treatment appropriately. SIRA's 2020 Best Practice Opioid Management Rapid Review and the 2025 Claims Management Reviews have made it clear: that duty now extends to active, proactive clinical oversight of opioid therapy. You cannot simply say "yes" to requests and hope for the best.

Understanding SIRA's 2020 Best Practice Opioid Management Rapid Review

In 2020, SIRA commissioned an evidence-based rapid review of opioid management in workers compensation. The findings were confronting. The review identified systemic gaps: opioids started without clear endpoints, chronic prescriptions that had become habit rather than necessity, insufficient multimodal pain management, and limited pharmacist oversight.

The review's core recommendation was unambiguous: opioids should not be treated as a default option for chronic non-cancer pain in workers compensation. Instead, the framework advocated for:

• Time-limited opioid trials (typically 3-6 months) with clear functional goals before chronic continuation
• Multimodal pain strategies combining physiotherapy, psychology, medication, and workplace intervention
• Proactive pharmacist involvement to screen for high-risk prescribing patterns
• Regular review cycles with documented functional progress

This wasn't a theoretical exercise. The review cited emerging evidence about opioid-induced hyperalgesia (where chronic opioid use actually increases pain sensitivity), tolerance (requiring ever-larger doses for the same effect), and the real addiction risk in a population often predisposed to dependency.

The 2025 Claims Management Reviews: Person-Centred Shift

SIRA's 2025 Claims Management Reviews built on this foundation but added critical nuance: the shift to a person-centred approach. Rather than applying blanket rules, the 2025 framework asks you to:

• Understand each worker's values, functional goals, and pain experience
• Involve them actively in prescribing decisions, not as passive recipients
• Support safe reduction and weaning when appropriate, not continuation for its own sake
• Recognize the psychological and social dimensions of pain and opioid dependency

The 2025 reviews also formalized the expectation that claims managers will refer for pharmacist-led medication review earlier and more frequently. This isn't optional or nice-to-have; it's embedded in SIRA's updated guidance on best-practice claims management.

Change 1: From Administrative Monitoring to Active Clinical Oversight

The shift from monitoring to oversight is fundamental. You are no longer a gatekeeper who approves or denies requests. You are a clinical facilitator who actively shapes the medication strategy.

What Active Clinical Oversight Looks Like

Before (Administrative Monitoring): Doctor requests opioid; you approve based on dose or indication; prescription continues; you ask for occasional reviews.

Now (Active Clinical Oversight): You request a medication review before chronic continuation; you establish functional goals; you require regular pharmacy reporting; you identify problematic patterns early and escalate to the doctor.

Proactive Pharmacist-Led Intervention

Independent pharmacist review is no longer a reactive afterthought. It should be:
Initiated early: Within the first 3 months of opioid prescription, not after years of chronic use.
Targeted at high-risk scenarios: Doses above 100 mg morphine equivalent daily, combination with benzodiazepines or Z-drugs, signs of problematic use, or functional plateau.
Linked to action: The pharmacist's report should trigger specific steps: dose adjustment, specialist consultation, weaning planning, or enhanced monitoring.

You should be referring for pharmacy review at least annually for any worker on chronic opioids, and more frequently if risk factors emerge. This is not optional paperwork; it is clinical oversight.

Standardised Pharmacy Reporting Framework

Effective oversight requires clear, actionable information. Your pharmacy partner should provide structured reporting on:

• Functional status: Is the worker doing more? Pain reduced? Returning to work? Or static despite high doses?
• Drug interactions and contraindications: Opioids with benzodiazepines, Z-drugs (zopiclone, zolpidem), gabapentinoids, or other CNS depressants?
• Tolerance and escalation patterns: Are doses creeping up without functional gain?
• Regulatory compliance: Are prescriptions flagged on PDMP (if applicable) as concerning?
• Person-centred readiness: Does this worker want to reduce? Are they experiencing side effects that suggest reduction might improve quality of life?

Change 2: Stringent Prescribing Safeguards

SIRA's reforms establish clear boundaries on opioid prescribing in workers compensation. Your role is to enforce these boundaries proactively.

The Default: Do Not Start

For chronic non-cancer pain, the default position is now: do not start opioids. Instead, default to multimodal strategies. Only initiate opioids if the worker has tried and benefited from physiotherapy, psychology, or other non-opioid pain management, or if there is clear clinical justification (e.g., severe acute trauma pain, palliative care).

This is a profound shift from historical practice. If you receive a request to start opioids for chronic lower back pain in a worker with no prior opioid exposure, your response should be: "Let's first refer for physiotherapy and psychology assessment. Opioids are a consideration only if multimodal treatment doesn't achieve functional improvement."

Time and Dose-Limited Trials

If opioids are initiated, they must come with an explicit time limit and functional endpoint. A reasonable framework:

• Duration: Maximum 3-6 months before formal review and decision on continuation
• Starting dose: Low; typically 10-20 mg morphine equivalent daily for opioid-naive workers
• Escalation ceiling: Any dose increase should be time-limited and dose-limited (e.g., up to 100 mg morphine equivalent daily for a 3-month trial)
• Functional gate: Continuation beyond the trial period requires documented functional improvement (e.g., increased activity, return to work, reduced pain interference with function)

You should see these parameters in the doctor's prescribing letter. If they are absent, ask for them.

Mandatory Weaning Plans

Any opioid prescription lasting beyond 6 months should include a weaning plan. This is not punitive; it is part of responsible prescribing. The plan should outline:

• The expected duration of opioid therapy (not "indefinite")
• Functional milestones at which dose reduction will occur
• The rate of reduction (typically 5-10% of total dose per month to minimize withdrawal)
• Support during weaning (e.g., pharmacy check-ins, psychology, physiotherapy for pain strategies)

Without a weaning plan, chronic opioid therapy becomes entrenched, and workers lose the opportunity to discover that they can function better off opioids than they thought.

Prohibitions: High-Risk Drug Combinations

Certain combinations are now considered unsafe in workers compensation and should trigger immediate escalation:

The presence of these combinations is not automatically a reason to stop treatment, but it is a clear trigger for intensified oversight and specialist involvement.

Change 3: Person-Centred Tapering and Safe Weaning Support

One of the most significant shifts in SIRA's 2025 guidance is the explicit recognition that opioid reduction must be done safely and with the worker's active involvement. You are no longer simply tapering doses; you are supporting safe, dignified reduction.

The Physiology of Weaning

Chronic opioid use produces physical dependence (distinct from addiction). Abrupt cessation or rapid reduction can trigger withdrawal: flu-like symptoms, anxiety, body aches, sweating, insomnia. A rational weaning plan acknowledges this and reduces slowly, typically 5-10% of the total daily dose per month, allowing the body to readjust.

Fast weaning is counterproductive; it leaves workers in pain and distress, and they often return to doctors requesting dose increases. Slow, supported weaning is more likely to succeed.

Function Over Pain Scores

Person-centred weaning focuses on function, not pain. A worker may initially feel worse pain as opioid doses fall (because opioid-induced hyperalgesia improves over weeks), but if they are sleeping better, more active, and engaging in life, the weaning is working. Your narrative around weaning should be: "This change is allowing you to move more, engage more with family, and ultimately feel better."

Education About Dependency, Tolerance, and Opioid-Induced Hyperalgesia

Workers often resist opioid reduction because they fear pain. Part of your role is educating them about the mechanism of opioid use:

• Tolerance: Over time, the same dose produces less pain relief. The brain adapts. This is why dose escalation often fails to improve function long-term.
• Opioid-Induced Hyperalgesia: Paradoxically, chronic opioids can increase pain sensitivity. Some workers report that after weaning, their pain is actually lower, not higher, because the hyperalgesia has resolved.
• Dependency: Physical dependence is not addiction. A worker can be physically dependent and not addicted (i.e., not misusing or losing control). But dependency means weaning must be slow and supported.

This education is best delivered by a pharmacist or pain psychologist, not by you as a claims manager. But you should reference it and support workers through the process.

Multimodal Support During Weaning

A weaning plan is not just a dose schedule; it is a package of support:

• Regular pharmacy review: Check-ins every 2-4 weeks to monitor withdrawal symptoms, adjust pace, troubleshoot.
• Pain psychology: Help the worker develop coping strategies, challenge catastrophic thinking about pain, build confidence in functioning without opioids.
• Physiotherapy and exercise: Gradual return to movement, with pain management strategies that do not rely on medication.
• Sleep hygiene and other non-opioid interventions: Address sleep, mood, and pain through behavioral approaches.

Workers are far more likely to succeed with weaning if they know they have coordinated, multidisciplinary support, not just a dose reduction schedule.

Change 4: Alignment with Clinical Guidelines and Specialist Advice

SIRA's reforms embed reference to contemporary clinical guidelines. As a claims manager, you should be familiar with the authoritative sources that inform opioid prescribing in Australia:

• Australian Medicines Handbook (AMH): Standard prescribing resource; notes cautions and contraindications
• Therapeutic Guidelines (Opioids and Pain Management modules): Evidence-based guidance on appropriate use, dose escalation limits, and non-opioid strategies
• Faculty of Pain Medicine guidelines: Expert consensus on chronic pain management, including opioid role and limitations
• SIRA's own guidance documents: Specific to workers compensation scheme

When prescribers propose opioid strategies outside these guidelines (e.g., dose escalation without functional gate, opioid use as monotherapy for chronic pain, opioids with benzodiazepines), your response should reference the guidelines: "The Therapeutic Guidelines recommend multimodal pain management for this presentation. Before approving this dose increase, let's ensure the worker is also engaged with physiotherapy and psychology."

Early Pain Medicine Specialist Involvement

Pain medicine specialists (physicians with advanced training in pain management) should be involved earlier in workers compensation claims involving chronic pain and opioids. You should consider a specialist consultation:

• Before opioid initiation if the pain is complex (e.g., neuropathic, mixed, high-disability)
• At the 3-6 month opioid trial endpoint, to advise on continuation or alternative strategies
• If prescribing is heading toward high-risk territory (doses over 100 mg morphine equivalent daily, combinations with benzodiazepines)
• Before initiating opioid weaning if the worker is high-risk or resistant

A specialist opinion costs your scheme money upfront but often prevents years of escalating costs from inappropriately managed chronic opioid use.

Practical Implementation Framework for Claims Managers

Theory is useful, but you need a roadmap. Here is a practical workflow for managing opioids in workers compensation claims under SIRA's reformed expectations.

Opioid Prescribing Decision Framework

Red Flag Escalation Pathway

Certain prescribing patterns should trigger immediate escalation to your medical advisor or specialists:

• Rapid dose escalation: More than 50% increase in 3 months without documented functional improvement or change in pain condition
• High-risk combinations: Opioids with benzodiazepines, Z-drugs, or gabapentinoids without specialist justification
• High-dose plateau: Doses above 100 mg morphine equivalent daily lasting more than 6 months without functional improvement or specialist oversight
• Compliance concerns: Multiple early repeats, prescriptions from multiple doctors, or pharmacy red flags for problematic use patterns
• Static function: Worker on chronic opioids for 12+ months with no documented improvement in pain, function, or work engagement

The Role of Independent Pharmacist-Led Review

Pharmacist-led medication review is not an optional adjunct to your claims management; it is a cornerstone of SIRA-compliant opioid oversight. Here is why, and how to use it effectively.

What a Pharmacist Review Provides That You Cannot

As a claims manager, you have access to prescriptions and reports, but a clinical pharmacist has expertise you do not:

• Drug interaction screening across all the worker's medications, including over-the-counter and complementary medicines
• Assessment of dose appropriateness against clinical guidelines and the worker's kidney/liver function
• Identification of tolerance patterns, dependency risk, and safer weaning strategies
• Person-centred consultation with the worker to understand their experience of medication, side effects, and readiness for change
• Written, structured recommendations actionable by doctors and you

A good pharmacist review answers the question: "Is this medication approach safe, appropriate, and aligned with the worker's goals?" Your job is to ensure these reviews happen and that recommendations are acted upon.

When to Refer for Pharmacy Review

Do not wait for a crisis or by accident. Refer for pharmacy review in these scenarios:

• Routine surveillance: All workers on chronic opioids at least annually
• Risk triggers: Any high-risk combination, dose above 100 mg morphine equivalent daily, signs of problematic use, or functional plateau
• Decision points: Before approving dose increases; at opioid trial endpoints; before weaning initiation
• New medication addition: Any new medication that interacts with opioids (e.g., benzodiazepine prescribed for anxiety) triggers a pharmacy review

Acting on Pharmacist Recommendations

A review is only valuable if you act on it. When the pharmacist recommends dose reduction, weaning, or a medication change, your next step should be to contact the prescribing doctor and say: "The pharmacist has recommended [action]. Can we discuss the rationale and next steps?" If the doctor disagrees, request written justification. If the recommendation aligns with guidelines and makes clinical sense, press the doctor to implement it.

Bringing It All Together: A Real-World Example

Let me walk you through a practical scenario that integrates all these principles.

Scenario: Sarah is a 45-year-old worker injured in a workplace accident 18 months ago. She sustained a lumbar spine injury, initially treated with acute opioids (20 mg morphine equivalent daily) for 6 weeks, then physiotherapy. At 6 months, acute pain persisted, and her doctor initiated chronic opioid therapy at 30 mg daily, with a target of "see how it goes." She was not referred for psychology or pain medicine input. Over the next year, her dose escalated to 80 mg daily in response to her reports of persistent pain. She also takes zopiclone 7.5 mg nightly for sleep. She has not worked since injury. Your recent pharmacy review flagged opioid-benzodiazepine concern and recommended specialist pain medicine input and opioid reduction planning.

Your Actions (SIRA-Compliant Approach):

1. Immediate: Contact Sarah's doctor and share the pharmacy review. Highlight the opioid + Z-drug concern (zopiclone is a Z-drug, equivalent to benzodiazepine risk). Request a time-bound response to the pharmacist's recommendations.
2. Specialist input: Refer to a pain medicine specialist for assessment. Ask the specialist to evaluate Sarah's pain, functional capacity, opioid appropriateness, and readiness for reduction.
3. Worker engagement: Meet with Sarah. Explain that your team is investigating whether her current medications are helping her feel and function better. Explain that a specialist and pharmacist will advise. Frame any changes as opportunities to improve quality of life, not punitive dose cuts.
4. Expect recommendations: The specialist will likely recommend zopiclone weaning (with sleep hygiene support), opioid dose reduction (to 50-60 mg daily initially), and psychology/physiotherapy intensification.
5. Coordinate reduction: Once agreed, refer back to the pharmacist to coordinate opioid and zopiclone weaning over 12 months, with psychology and physiotherapy support. Schedule monthly pharmacy check-ins.
6. Monitor progress: At 6 months, review function, pain, sleep, engagement with rehabilitation. If Sarah is sleeping better, moving more, and engaging with physiotherapy despite lower opioid doses, the reduction is working. If she is struggling, slow the reduction and intensify non-opioid support.

This approach is compliant with SIRA's 2020 and 2025 guidance because it is active, proactive, specialist-informed, person-centred, and supported.

Navigating Doctor Pushback

Not every doctor will embrace these changes. You may face resistance to your clinical oversight role. Here is how to navigate it:

Doctor says: "The worker needs this opioid dose. It's their preferred treatment."

You respond: "We support the worker's preferences, and we also have a duty under the Workers Compensation Act 1987 to manage medication safely and evidence-based. The Therapeutic Guidelines recommend multimodal pain management and functional gates for opioid continuation. Can we discuss the worker's functional status since opioid initiation, and whether they've engaged with physiotherapy and psychology?"

Doctor says: "Reducing opioids will cause the worker to fail."

You respond: "We agree that rapid reduction could be harmful. That's why we're proposing a slow, supported reduction with pharmacy oversight, psychology, and physiotherapy. Many workers find that gradual reduction improves function once tolerance and opioid-induced hyperalgesia resolve. Let's refer to pain medicine to advise on the safest approach for this worker."

Doctor says: "This is not my problem; it's the insurer's."

You respond: "We are partners in the worker's care under the Workers Compensation Act. SIRA expects both prescribers and insurers to proactively manage opioid therapy. We cannot move forward without the prescriber's involvement. If there is a difference of opinion on the appropriate approach, let's seek a third-party specialist opinion."

You have the legitimate authority to ask these questions and expect engagement. Lean on SIRA guidance and contemporary clinical guidelines.

Key Takeaways: Your New Role as a Claims Manager

SIRA's 2020 and 2025 reforms have redefined your role. You are no longer simply approving or denying prescriptions. You are:

• A clinical facilitator who shapes the medication strategy toward multimodal, person-centred, evidence-based pain management
• An escalation manager who identifies red flags and triggers specialist input early
• A coordinator who ensures pharmacists, doctors, psychologists, and physiotherapists are aligned and communicating
• An advocate for the worker's functional recovery, not just pain scores

This requires you to know the clinical territory, to reference guidelines confidently, to involve pharmacists proactively, and to engage doctors as partners. It is more sophisticated than administrative gatekeeping, but it is also more effective. Workers who receive this level of integrated, proactive medication management have better outcomes: less chronic opioid use, better function, higher rates of return to work, and lower overall claim costs.